Syngenta Group

Who owns Syngenta Group?
Syngenta Group is wholly owned by Sinochem Holdings Corporation, a Chinese state-owned enterprise formed in 2021 from the merger of Sinochem Group and ChemChina. Ultimate control rests with the Chinese government via SASAC.

Is Syngenta Group publicly traded?
No. It is privately held by its state parent. A planned STAR Market IPO in Shanghai received approval in 2023 but was withdrawn in 2024, and no listing has occurred as of November 2026.

Where is Syngenta Group headquartered?
The group is legally domiciled in Shanghai, China, as Syngenta Group Co., Ltd., while its management headquarters is in Basel, Switzerland.

How much revenue does Syngenta Group make?
The group reported $28.4 billion in sales for fiscal year 2025 with EBITDA of $4.4 billion, a 15.4 percent margin.

What are Syngenta Group's business units?
Four: Syngenta Crop Protection in Basel, Syngenta Seeds in Chicago, ADAMA in Tel Aviv, and Syngenta Group China in Shanghai.

When did China acquire Syngenta?
ChemChina completed its $43 billion acquisition of Syngenta AG in June 2017, then combined it with ADAMA and Sinochem agricultural assets into Syngenta Group in 2020.

The group's oldest roots lie in the Swiss chemical industry. Geigy, Ciba, and Sandoz all developed crop protection products in the early and mid-twentieth century. Ciba-Geigy formed in 1970, merged with Sandoz to create Novartis in 1996, and in 2000 Novartis spun off its agribusiness to merge with Zeneca Agrochemicals, the crop science arm spun out of Britain's ICI via AstraZeneca. The merged entity, Syngenta AG, began trading in November 2000 as the world's largest dedicated agrochemical company.

Syngenta spent its first fifteen years as a public company listed in Zurich and New York, building a seeds business through acquisitions and maintaining a leading crop protection position. In 2015 Monsanto attempted to acquire it for more than $46 billion, a bid Syngenta's board rejected over regulatory risk.

China National Chemical Corporation, ChemChina, stepped in with an agreed $43 billion all-cash offer in February 2016, at the time the largest overseas acquisition by a Chinese company. The deal closed in June 2017 after approvals from regulators in the United States, Europe, and China, and Syngenta was delisted.

In 2020, ChemChina reorganized its agricultural holdings into Syngenta Group, placing Syngenta AG, ADAMA (acquired 2011), and Sinochem's fertilizer, seed, and distribution operations under one roof domiciled in Shanghai. The 2021 merger of ChemChina and Sinochem Group into Sinochem Holdings transferred ultimate ownership to the new parent.

Syngenta Group pursued a STAR Market IPO in Shanghai, filing in 2021 and receiving approval in 2023 for what would have been one of the largest listings in Chinese history. The offering was withdrawn in 2024 amid weak market conditions, and as of November 2026 the company remains wholly state-owned with no formal decision made on a future listing.

The group publishes an annual ESG report and commits to science-based climate targets, regenerative agriculture programs, and reduced carbon intensity across operations. Its 2025 ESG report was prepared under Chinese CASS-ESG guidelines with GRI alignment, and selected KPIs received limited assurance from KPMG.

Product-level controversies are significant. Atrazine remains widely sold in the United States while banned in the EU. Paraquat, restricted in many countries, faces a large multidistrict litigation in the US alleging links to Parkinson's disease, which the company disputes. Neonicotinoid seed treatments associated with pollinator harm are restricted across Europe. The group defends the registered products while investing in biologicals and lower-impact chemistries as hedges.

Syngenta Group was named a top agricultural employer in Science magazine's annual rankings for the ninth consecutive year in 2025. Its research units regularly win industry recognition for new active ingredients, and the group has been cited for farmer-facing sustainability programs in emerging markets.

Beyond product litigation, the group faces structural political scrutiny. The original 2017 acquisition passed CFIUS review with conditions, but subsequent US legislative proposals have targeted Chinese ownership of agricultural assets and data. A US EPA settlement in prior years addressed seed facility violations. The withdrawn IPO also drew attention to the group's debt load carried from the acquisition era, which it has been reducing through improved EBITDA and cash flow.